|Budget Amount *help
¥2,100,000 (Direct Cost: ¥2,100,000)
Fiscal Year 1994: ¥700,000 (Direct Cost: ¥700,000)
Fiscal Year 1993: ¥1,400,000 (Direct Cost: ¥1,400,000)
KHM-10B was established from a patient with Burkitt's lymphoma. Conventional cytogenetic analysis revealed no detectable 8q24 involvement, and the rearrangement of c-myc oncogene could not detected by Southern blot study. However, fluorecence in situ hybridization (FISH) assay identified masked t(8 ; 22)(q24 ; q11) which is the 22q11 portion was translocated to the 8q24 locus. Using hydroxyurea and thimidine, the KHM-10B cells were arrested at S phase, and the syncronized cells progressed the cell cycle in drug free medium. The constitutive expressions of c-myc and max were observed throughout the cell cycle ; as was found in another Burkitt's lymphoma cell line, Raji.
KHM-11 was established from the pleural effusion of a patient with IgA-kappa type aggresive myeloma with high serum lactate dehydrogenase who was extermely resistant to vincristin, adriamycin and dexamethasone combination therapy (VAD). In addition to the expression of regular plasma cell antigens, CD38 and PCA-1, CD45 was found on both fresh cells and KHM-11. Other T-or B-cell antigens, such as CD2,4,8,19 and 20 were negative. IL-6 was found in the culture supernatant of KHM-11, and this supernatant stimulated the growth of this cell lines, indicating an IL-6 autocrine mechanism. These findings indicate that KHM-11 is a CD45-positive immature plasma cell line.
Both cell lines, KHM-10B and KHM-11 should be a useful tool for understanding the pathogenesis of B cell maliganancies.